Categories: Health

Carlsmeds aprevo Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures

 | Source: Carlsmed

CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the Centers for Medicare & Medicaid Services (CMS) granted New Technology Add-On Payment (NTAP) reimbursement to cervical fusion procedures using the company’s aprevo® personalized interbody implants.

The NTAP program is designed to provide additional reimbursement to hospitals that use designated new medical technologies in the first few years of market introduction. These new technologies demonstrate significant clinical improvement in diagnosis or treatment for Medicare beneficiaries compared to existing alternatives. Starting October 1, 2025, through the NTAP program, cervical fusion procedures utilizing Carlsmed’s aprevo® devices are eligible for additional payment from CMS and private payors. The NTAP will use unique ICD-10-PCS procedure codes and provide up to an additional $21,125 in reimbursement on top of the Medicare Severity-Diagnosis Related Groups (MS-DRGs) for qualifying inpatient procedures.

“We appreciate CMS’s support in making innovative medical technologies more accessible to Medicare beneficiaries by mitigating some of the financial burden on hospitals,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “Our aprevo® personalized surgery platform is designed to reduce the need for revision surgeries and empower surgeons to achieve optimal alignment for each patient. Building upon the CMS reimbursement granted to our lumbar fusion devices last year, we are pleased that this decision enables us to continue our mission to improve outcomes and decrease the cost of healthcare for spine surgery patients.”

The aprevo® devices are designed to match the unique anatomical and alignment needs of each patient through Carlsmed’s proprietary AI-powered surgical planning platform and digital production system. Carlsmed received Breakthrough Device designation for cervical use by the FDA and anticipates a U.S. commercial launch in 2026.

About Carlsmed 
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects, including statements about the Company’s current expectation of launching aprevo® cervical in the United States in 2026 and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations 
IR@Carlsmed.com 

Media 
LeAnn Burton 
Senior Director Brand Marketing 
LBurton@Carlsmed.com 

GlobeNews Wire

Recent Posts

Tevogen Recognized in BINJEs BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the…

6 hours ago

Branded Legacy, Inc. Forms Strategic Partnership with Stanford University’s Dr. Eran Bendavid to Advance Addiction Solutions

VANCOUVER, British Columbia, Aug. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc.…

6 hours ago

FED Fitness Expands Its Amazon Best Seller Lineup: Shaping the Future of Home Fitness for Quality-Focused Families

Hong Kong, China , Aug. 23, 2025 (GLOBE NEWSWIRE) -- FED Fitness is taking a…

10 hours ago

UltraVizion Antenna Delivers Free HD and 4K Channels in 2025 Without Monthly Bills

New York, Aug. 23, 2025 (GLOBE NEWSWIRE) -- This press release is for informational purposes…

10 hours ago

TOEFL ESSENTIALS: A RELIABLE ENGLISH TEST SOON AVAILABLE FOR CANADIAN IMMIGRATION APPLICATIONS

PRINCETON, N.J., Aug. 21, 2025 /PRNewswire/ -- ETS, a global leader in education and talent…

15 hours ago

Binti Launches First-of-its-Kind “AI for Social Services” Offering with Anthropic, Unleashing AI to Its Customer Base of Agencies Serving 46% of Child Welfare Across the U.S.

Collaboration falls under Anthropic's "AI for Good" focus. Through embedding Claude, Binti will help social…

15 hours ago